Author

Li Wang

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Network pharmacology and experimental verification reveal the mechanism of hederagenin in suppressing podocyte injury in focal segmental glomerular sclerosis.

BACKGROUND Podocyte injury is a pivotal driver of chronic kidney disease (CKD) progression in focal segmental glomerulosclerosis (FSGS). Although hederagenin (HDG) has shown promise in the treatment of CKD, its specific protective effects against podocyte injury in FSGS, along with its underlying pharmacological mechan...

Xinyuan Tian, Rang-yue Han, Xiao-Jiao Gu et al. · Clinical Nephrology · 0 citations

Sep 2026

Complanatuside Ameliorates Renal Injury and Fibrosis in Chronic Kidney Disease by Inhibiting Tubular Cell Apoptosis via Activation of KLK1/BDKRB2.

BACKGROUND Chronic kidney disease (CKD) is characterized by renal fibrosis as a key pathological feature. Total flavonoids extracted from Astragalus complanatus can effectively alleviate renal fibrosis. However, the anti-fibrotic effect and the underlying specific mechanisms of its main active component, Complanatuside...

Jing Gao, Rui-Zhi Tan, Ke Deng et al. · Journal of Nutritional Bioch... · 0 citations

Review Aug 2026

The Therapeutic Application of Epigenetic Regulation by Natural Herbal Compounds in Kidney Diseases.

Kidney diseases, represented by chronic kidney disease (CKD) and acute kidney injury (AKI), pose significant global public health challenges due to their complex pathogenesis and limited therapeutic options. In recent years, epigenetic regulation-including DNA methylation, histone modifications, and non-coding RNAs-has...

Qiu-xiang Bai, Kang Luo, Long-hao Jia et al. · Seminars in Nephrology · 0 citations